Patient Reported Outcomes in Friedreich's Ataxia Patients After Withdrawal From Treatment With Idebenone (PROTI)
Status:
Completed
Trial end date:
2012-07-01
Target enrollment:
Participant gender:
Summary
This is a Phase IIIb Double-Blind, Randomised, Placebo-Controlled Study. The aim is to
further investigate the effects of idebenone in patients with Friedreich's ataxia.
The objective of the PROTI study is to establish whether patients can correctly determine
which treatment assignment (placebo or idebenone) they received during the randomised phase
of the trial, and identify any potential changes on symptoms or activities.